Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alzamend NeuroALZN +0.75%21 PB Ratio is 6.94 as of Jul. 28, 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,228 Biotechnology companies, Alzamend Neuro ranks worse than 79.15% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-28), Alzamend Neuro's share price is $1.34. Alzamend Neuro's Book Value per Share for the quarter that ended in Apr. 2026 was $0.19. Hence, Alzamend Neuro's PB Ratio of today is 6.94.
The historical rank and industry rank for Alzamend Neuro's PB Ratio or its related term are showing as below:
ALZN'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 7.05
Current: 7.05
During the past 8 years, Alzamend Neuro's highest PB Ratio was 7.05. The lowest was 0.00. And the median was 0.00.
ALZN's PB Ratio is ranked worse than 79.15% of 1228
companies
in the Biotechnology industry
Industry Median: 2.78
vs ALZN: 7.05
During the past 12 months, Alzamend Neuro's average Book Value Per Share Growth Rate was -96.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -83.40% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Alzamend Neuro was 234.30% per year. The lowest was -83.40% per year. And the median was -11.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alzamend Neuro PB Ratio Related Terms
Alzamend Neuro PB Ratio Historical Data
* Premium members only.
The historical data trend for Alzamend Neuro's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alzamend Neuro's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Alzamend Neuro's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alzamend Neuro (ALZN) has a PB Ratio of 6.94 as of Jul. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alzamend Neuro and its competitors. According to the industry distribution chart, Alzamend Neuro ranks #972 out of 1228 companies in the Biotechnology industry, placing it in the top 79.2%.
Is Alzamend Neuro's PB Ratio too high?
Alzamend Neuro's current PB Ratio is 6.94. The Biotechnology industry median PB Ratio is 2.78. Alzamend Neuro's value of 6.94 is 149.6% above this industry median. Based on the distribution chart, Alzamend Neuro ranks #972 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's PB Ratio compare to SILO and BGMS?
According to the Biotechnology industry distribution chart, Alzamend Neuro ranks #972 out of 1228 companies for PB Ratio. This places Alzamend Neuro in the lower half of its industry. The industry median PB Ratio is 2.78. Alzamend Neuro's value of 6.94 is 149.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.78, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alzamend Neuro's current PB Ratio of 6.94 is 149.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alzamend Neuro and its competitors. For the Biotechnology industry, the median PB Ratio is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alzamend Neuro's current PB Ratio is 6.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current PB Ratio of 6.94. The current PB Ratio is 6.94 and 149.6% above the Biotechnology industry median of 2.78. Alzamend Neuro's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current PB Ratio is 6.94 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score
Get the complete analysis for ALZN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALZN has been successfully added to your 
